Redefining Anthraquinone-based Anticancer Drug Design through Subtle Chemical Modifications

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Anthraquinones are established anticancer drugs (e.g., doxorubicin) but exhibit significant toxicity, particularly cardiomyopathy.
• Structural modifications of anthraquinones are explored to develop safer and more effective chemotherapeutic agents.
• The anthraquinone scaffold's properties facilitate DNA intercalation and topoisomerase-II inhibition, crucial for anticancer activity.

Purpose of the Study:

• To review structural modifications of anthraquinone derivatives over the past decade.
• To highlight the development of potent and less toxic anticancer agents.
• To explore the potential of molecular hybrids in anticancer drug discovery.

Main Methods:

• Review of recent literature on anthraquinone derivative synthesis and evaluation.
• Analysis of structure-activity relationships for anticancer properties.
• Investigation of molecular hybrid strategies for multi-target drug development.

Main Results:

• Structural modifications improve anticancer potency, selectivity, and reduce toxicity.
• Functional group incorporation enhances biological target interactions.
• Molecular hybrids demonstrate multi-target activity and reduced adverse effects.

Conclusions:

• Anthraquinone derivatives offer a promising scaffold for developing novel anticancer drugs.
• Strategic structural modifications and hybrid approaches can yield potent agents with improved safety profiles.
• Further research into these modifications holds potential for overcoming drug resistance and enhancing cancer treatment.